GENinCode PLC Issue of Share Options (2521H)
23 November 2022 - 6:44PM
UK Regulatory
TIDMGENI
RNS Number : 2521H
GENinCode PLC
22 November 2022
GENinCode Plc
("GENinCode" or the "Company")
Issue of Share Options
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics
company focused on the prevention of cardiovascular disease
("CVD"), announces that under its Company Share Option Scheme plan,
it has granted 200,000 share options to Felix Frueh, Non-Executive
Director. Felix joined the Board of GENinCode Plc earlier this
year.
The share options were granted at an exercise price of 44p per
share and will vest over three years.
The issue of the share options does not affect the number of
shares in issue or the voting rights of GENinCode Plc. The number
of shares in issue remains at 95,816,866.
PDMR Disclosure
The notifications below, made in accordance with the
requirements of the EU Market Abuse Regulation, provide further
detail on the director's share dealing.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Felix Frueh
------------------------------------- ---------------------------------
2 Reason for the notification
------------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------------------- ---------------------------------
b) Initial notification Initial Notification
/Amendment
------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a) Name GENinCode plc
------------------------------------- ---------------------------------
b) LEI 213800UX6TE7K6502892
------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------
a) Description of the Ordinary shares of 1p each
financial instrument,
type of instrument
Identification code ISIN: GB00BL97B504
b) Nature of the transaction Issue of Options
------------------------------------- ---------------------------------
c) Price(s) and volume(s)
-------------- --------------
Price(s) Volume(s)
-------------- --------------
44p 200,000
-------------- --------------
d) Aggregated information
- Aggregated volume 200,000
- Price 44p
e) Date of the transaction 22 November 2022
------------------------------------- ---------------------------------
f) Place of the transaction Off market
------------------------------------- ---------------------------------
For more information visit www.genincode.com
GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO
Paul Foulger, CFO
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Tel: +44 (0)20 7710 7600
Alex Price / Ben Maddison / Richard Short
Cenkos Securities Plc (Joint Broker) Tel: +44 (0)20 7397 8900
Giles Balleny
Dale Bellis / Michael Johnson (Sales)
Walbrook PR Limited Tel: 020 7933 8780 or
Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage genincode@walbrookpr.com
About GENinCode
GENinCode Plc is a UK based company specialising in genetic risk
assessment of cardiovascular disease. Cardiovascular disease is the
leading cause of death and disability worldwide.
GENinCode operates business units in the UK, in the United
States through GENinCode U.S. Inc and in Europe through GENinCode
S.L.U.
GENinCode predictive technology provides patients and physicians
with globally leading preventative care and treatment strategies.
GENinCode CE marked invitro-diagnostic molecular tests combine
clinical algorithms and bioinformatics to provide advanced patient
risk assessment to predict disease onset.
About Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of death
globally, taking an estimated 17.9 million lives each year. CVD is
a group of disorders of the heart and blood vessels and include
coronary heart disease, cerebrovascular disease, rheumatic heart
disease and other conditions. More than four out of five CVD deaths
are due to heart attacks and strokes, and one third of these deaths
occur prematurely in people under 70 years of age.
The most important behavioural risk factors of heart disease and
stroke are unhealthy diet, physical inactivity, tobacco use and
harmful use of alcohol. The effects of behavioural risk factors may
show up in individuals as raised blood pressure, raised blood
glucose, raised blood lipids, and overweight and obesity. These
"intermediate risks factors" can be measured in primary care
facilities and indicate an increased risk of heart attack, stroke,
heart failure and other complications.
Cessation of tobacco use, reduction of salt in the diet, eating
more fruit and vegetables, regular physical activity and avoiding
harmful use of alcohol have been shown to reduce the risk of
cardiovascular disease. Health policies that create conducive
environments for making healthy choices affordable and available
are essential for motivating people to adopt and sustain healthy
behaviours.
Identifying those at highest risk of CVDs and ensuring they
receive appropriate treatment can prevent premature deaths. Access
to noncommunicable disease medicines and basic health technologies
in all primary health care facilities is essential to ensure that
those in need receive treatment and counselling.
CVD causes a quarter of all deaths in the UK and is the largest
cause of premature mortality in deprived areas and is the single
biggest area where the NHS can save lives over the next 10 years.
CVD is largely preventable, through lifestyle changes and a
combination of public health and NHS action on smoking and tobacco
addiction, obesity, tackling alcohol misuse and food
reformulation.
Genetic risk assessment enables early detection and treatment of
CVD to help patients live longer , healthier lives. Too many people
are still living with undetected, high-risk conditions such as high
blood pressure, raised cholesterol, and atrial fibrillation (AF).
Progress continues in the NHS to identify and diagnose people early
and routinely knowing their 'ABC' (testing and monitoring AF, Blood
pressure and Cholesterol) set out in the NHS 10 Year plan.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGZMZMDZFGZZM
(END) Dow Jones Newswires
November 22, 2022 09:07 ET (14:07 GMT)
Genincode (LSE:GENI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Genincode (LSE:GENI)
Historical Stock Chart
From Jul 2023 to Jul 2024